Search Results (30)
Click the Why column to see why an item matched the search.
| Match | Type | Why |
|---|
| Proteasome beta subunit pharmacogenomics: gene resequencing and functional genomics. | Academic Article |
Why?
|
| Gaedigk, Andrea | Person |
Why?
|
| Translating pharmacogenetics and pharmacogenomics into drug development for clinical pediatrics and beyond. | Academic Article |
Why?
|
| Identifying genomic and developmental causes of adverse drug reactions in children. | Academic Article |
Why?
|
| DPYD Genotyping Recommendations: A Joint Consensus Recommendation of the Association for Molecular Pathology, American College of Medical Genetics and Genomics, Clinical Pharmacogenetics Implementation Consortium, College of American Pathologists, Dutch Pharmacogenetics Working Group of the Royal Dutch Pharmacists Association, European Society for Pharmacogenomics and Personalized Therapy, Pharmacogenomics Knowledgebase, and Pharmacogene Variation Consortium. | Academic Article |
Why?
|
| Leeder, J. Steven | Person |
Why?
|
| Children’s Mercy Hospital Collaborative Fellowship Program in Pediatric Pharmacology | Grant |
Why?
|
| Children’s Mercy Hospital Collaborative Fellowship Program in Pediatric Pharmacology | Grant |
Why?
|
| Clinical pharmacogenomic testing and reporting: A technical standard of the American College of Medical Genetics and Genomics (ACMG). | Academic Article |
Why?
|
| Wagner, Jonathan | Person |
Why?
|
| Fridley, Brooke | Person |
Why?
|
| A Bayesian integrative genomic model for pathway analysis of complex traits. | Academic Article |
Why?
|
| Merging pharmacometabolomics with pharmacogenomics using '1000 Genomes' single-nucleotide polymorphism imputation: selective serotonin reuptake inhibitor response pharmacogenomics. | Academic Article |
Why?
|
| Pharmacogenetics in American Indian populations: analysis of CYP2D6, CYP3A4, CYP3A5, and CYP2C9 in the Confederated Salish and Kootenai Tribes. | Academic Article |
Why?
|
| Developmental pharmacogenetics in pediatric rheumatology: utilizing a new paradigm to effectively treat patients with juvenile idiopathic arthritis with methotrexate. | Academic Article |
Why?
|